President, Research and Development · Revolution Medicines, Inc. (RVMD)

Stephen FRCPath

FY2025 is the first fiscal year CompBrief holds for Stephen FRCPath as a named executive officer of Revolution Medicines; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$5,963,229

Salary $625,833Stock awards $1,491,084

2nd of 6 named executive officers at Revolution Medicines by FY2025 total.

6 named officers on file for Revolution Medicines, FY2025

Stephen FRCPath’s pay file — $29

  • 1 fiscal year of pay, line by line
  • RVMD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Revolution Medicines’s whole pay program stands against its peers

  • Revolution Medicines’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RVMD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Free

Get Stephen FRCPath’s full pay file as a PDF — free

More than this page: up to 10 years of Stephen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Stephen FRCPath compensation by year

Revolution Medicines Summary Compensation Table · the one fiscal year held
In US dollars, as Revolution Medicines reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$625,833
Bonus$0
Stock awards$1,491,084
Option awards$3,378,112
Non-equity incentive$461,200
Pension and deferred compensation$0
All other$7,000
Total$5,963,229

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revolution Medicines, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182453, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Revolution Medicines, Inc. filed document, accession 0001193125-26-182453. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

Revolution Medicines’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Mark GoldsmithPresident and Chief Executive Officer$14,672,390
Stephen FRCPath · this pagePresident, Research and Development$5,963,229
Stephen KelseyPresident, Research and Development$5,963,229
Margaret HornChief Operating Officer$4,821,057
Jeffrey CisliniGeneral Counsel and Secretary$3,718,589
Jack AndersChief Financial Officer$3,588,111

The full Revolution Medicines compensation record

free company brief

This page is one person within Revolution Medicines's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Revolution Medicines proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revolution Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen FRCPath's compensation dossier · One-time report. No refunds.